A- A A+

USA. Opioide: So manipulierte Pharmakonzern die öffentliche Meinung

Der Schmerzmittelhersteller Purdue finanzierte Ärzte, Patientenorganisation und «Think Tanks». Viele Medien fielen darauf herein. (infosperber.ch, Schweiz, 05.12.2019)

https://www.infosperber.ch/Artikel/Wirtschaft/Opioide-So-manipulierte-Pharmakonzern-die-offentliche-Meinung

USA. Deal will let more companies make overdose antidote spray

More companies could begin making an easy-to-use version of an opioid overdose antidote under a deal announced Thursday by New York's attorney general. (MedicalXpress, USA, 02.01.2020)

https://medicalxpress.com/news/2020-01-companies-overdose-antidote.html

USA. American Pot Is The Gold Standard. But Canada Leads The Export Game — For Now.

(…) After 20 years of experience, legal marijuana growers in the U.S. have the reputation of creating the best product in the world, scientifically grown and tightly regulated for quality and safety.

The crop would be in high demand internationally — perhaps the centerpiece of a new U.S. industry — if not for the regulatory conundrum in which growers operate:

Because marijuana is legal in many states but still illegal federally, marijuana growers are unable to ship their products to other countries or even other American states that have legalized the drug. So while U.S. cannabis firms have driven product innovation and mastered the science of large-scale grow operations, they restlessly wait for the export curtain to lift. (Califormia Health Line, USA, 03.01.2020)

https://californiahealthline.org/news/grade-a-all-american-pot-the-next-big-export

Expertinnen kritisieren Kinderrechtsverletzungen im Tabakanbau

Heidelberg/Berlin – Der Konsum von Tabakerzeugnissen ist vor allem für junge Menschen gesundheitsschädlich – aber auch unter der Produktion können Kinder und Jugendliche enorm leiden. Auf die gefährliche Kinderarbeit im globalen Süden machen das Deutsche Krebsforschungszentrum (DKFZ) und das Projekt Unfairtobacco aufmerksam. (aerzteblatt.de, 02.01.2020)

https://www.aerzteblatt.de/nachrichten/108447/Expertinnen-kritisieren-Kinderrechtsverletzungen-im-Tabakanbau

Wie reich ist Familie Sackler? : Die Profiteure der Opioid-Krise 

Purdue Pharma steht im Zentrum von Amerikas Opioid-Krise. Die Eigentümerfamilie hat hohe Dividenden kassiert. Zudem wird ihr vorgeworfen, die Patienten nicht nur süchtig, sondern auch an den Gegenmitteln verdient zu haben. (Frankfurter Allgemeine Zeitung, 17.12.2019)

https://www.faz.net/aktuell/wirtschaft/unternehmen/profiteure-der-opioid-krise-wie-reich-ist-familie-sackler-16540744.html

Sackler-owned opioid maker goes global with OD treatment

The gleaming white booth towered over the medical conference in Italy in October, advertising a new brand of antidote for opioid overdoses. “Be prepared. Get naloxone. Save a life,” the slogan on its walls said.

Some conference attendees were stunned when they saw the company logo: Mundipharma, the international affiliate of Purdue Pharma — the maker of the blockbuster opioid, OxyContin, widely blamed for unleashing the American overdose epidemic.

Here they were cashing in on a cure. (Businees Insider, 15.12.2019)

https://www.businessinsider.com/sackler-owned-opioid-maker-goes-global-with-od-treatment-2019-12

USA. Sacklers Withdrew Over $10 Bln in a Decade From Purdue Pharma

The Sackler family - owners of Purdue Pharma - transferred more than $10 billion in a decade from the OxyContin maker to its trusts and holding companies, the New York Times reported on Monday, citing a new audit commissioned by the drugmaker. (Medscape, 1.12.2019)

https://www.medscape.com/viewarticle/922759

China/USA. Opioidkrise: Irreführende Werbung treibt Schmerzmittelabsatz in China voran

In den USA hat der Pharmahersteller Purdue mit dem Schmerzmittel Oxycontin die tödlichste Drogenepidemie der Geschichte ausgelöst. Jetzt rollt er den chinesischen Markt auf - mit den gleichen fragwürdigen Methoden. (spiegel.de, 20.11.2019)

https://www.spiegel.de/wirtschaft/unternehmen/irrefuehrende-werbung-treibt-schmerzmittelabsatz-in-china-voran-a-1297372.html

China/USA. Oxy sales in China driven by misleading addiction claims

Thousands of lawsuits across the United States have accused a drug company owned by the billionaire Sackler family of using false claims to push highly addictive opioids on an unsuspecting nation, fueling the deadliest drug epidemic in U.S. history. 

Yet, even as its U.S. drugmaker collapses under the charges, another company owned by the family has used the same tactics to peddle its signature painkiller, OxyContin, in China, according to interviews with current and former employees and documents obtained by the Associated Press.

The documents and interviews indicate that representatives from the Sacklers' Chinese affiliate, Mundipharma, tell doctors that time-release painkillers like OxyContin are less addictive than other opioids—the same pitch that Purdue Pharma, the U.S. company owned by the family, admitted was false in court more than a decade ago. (medicalXpress, USA, 20.11.2019)

https://medicalxpress.com/news/2019-11-oxy-sales-china-driven-addiction.html

Was bringen Werbeverbote für Tabak oder Alkohol? Evidenz aus zwei Cochrane-Reviews

Sollte man in Deutschland öffentliche Werbung für Tabak, etwa im Kino oder auf Plakatwänden, verbieten, um insbesondere junge Menschen vor Abhängigkeit zu schützen? Die Frage erhitzt zurzeit erneut die Gemüter. Auch Werbeverbote für Alkohol, E-Zigaretten, Fastfood oder ungesunde Kindernahrungsmittel stehen zur Diskussion. Eine zentrale Frage dabei lautet, wie groß der Effekt von Werbeverboten wirklich ist. Zwei bereits vor einiger Zeit in der Cochrane Library erschienene systematische Übersichtsarbeiten fassen Evidenz zu diesem Thema zusammen und könnten zu einer Versachlichung der Debatte beitragen. (Cochrane Deutschland Stiftung (CDS), 04.12.2019)

https://idw-online.de/de/news728421

Experten schlagen spürbare Preiserhöhungen für Zigaretten vor

Berlin – Experten des Deutschen Krebsforschungszentrums (DKFZ) haben sich für spür­bare Preis­erhöhungen von Zigaretten ausgesprochen. „Wir schlagen eine Steuererhöhung von 30 Prozent in drei Schritten vor“, sagte Ute Mons vom DKFZ heute anlässlich der 17. Deutschen Konferenz für Tabakkontrolle in Heidelberg. (aerzteblatt.de, 04.11.2019)

https://www.aerzteblatt.de/nachrichten/107889/Experten-schlagen-spuerbare-Preiserhoehungen-fuer-Zigaretten-vor

USA. How Juul Hooked a Generation on Nicotine

The company planted the seeds of a public health crisis by marketing to millennials, who had low smoking rates, and it ignored evidence that teenagers were using its products. (New York Times, 23.11.2019)

https://www.nytimes.com/2019/11/23/health/juul-vaping-crisis.html

Uncovering the Truth Behind The Global Cannabis Industry Slump

With stocks in the cannabis industry climbing to record highs at the end of last year, 2019 was supposed to be the most prosperous year yet for the cannabis industry. Adult-use cannabis had become legal in Canada and medical legislation was creeping across the globe, driving press coverage and investor confidence to all-new heights. However, 12 months later, shares in major cannabis stocks have reached a nine-month low, and no imminent legislative decisions or major industry deals look capable of reversing the crash in the short-term. As we approach the close of the year, we examine whether the industry faces a burst bubble or a market correction. (Prohibition Partners, London/Barcelona/Dublin, 03.12.2019)

https://prohibitionpartners.com/2019/12/03/the-truth-behind-the-global-cannabis-industry-slump/

USA. Drugmakers, distributors facing federal opioid probe

At least a half-dozen companies that make or distribute prescription opioid painkillers are facing a federal criminal investigation over whether they violated federal law as they shipped more drugs amid the growing nationwide addiction and overdose crisis. (MedicalXpress, USA, 27.11.2019)

https://medicalxpress.com/news/2019-11-drugmakers-distributors-federal-opioid-probe.html

Afrika. Afrika strebt Führungsrolle beim Export von Cannabis an

Kapstadt – Afrikanische Länder werden nach Ansicht von Experten im Anbau von Canna­bis für medizinische Zwecke eine führende Rolle auf dem Weltmarkt einnehmen. Davon gingen Teilnehmer der Konferenz „CannaTech“ heute in Kapstadt aus. Dort kamen mehr als 500 Wissenschaftler, Unternehmer und Gründer der internationalen Cannabisindustrie zusammen. (aerzteblatt.de, 25.11.2019)

https://www.aerzteblatt.de/nachrichten/107671/Afrika-strebt-Fuehrungsrolle-beim-Export-von-Cannabis-an

USA. US-Behörden stellen Pharmaunternehmen auf eine Stufe mit Drogendealern

New York – Pharmaunternehmen, die Schmerzmittel produzieren, könnte in den USA nach einem Zeitungsbericht weiterer großer rechtlicher Ärger drohen. Die Justizbehörden prüfen im Rahmen einer strafrechtlichen Untersuchung offenbar, ob Hersteller und Händ­ler abhängig machender Opioide gegen das bundesweite Suchtmittelgesetz „Controlled Substances Act“ verstoßen haben. Das schrieb das Wall Street Journal unter Berufung auf Insider. Die Ermittlung stehe aber noch am Anfang. (aerzteblatt.de, 27.11.2019)

https://www.aerzteblatt.de/nachrichten/107733/US-Behoerden-stellen-Pharmaunternehmen-auf-eine-Stufe-mit-Drogendealern

China/USA. Oxy sales in China driven by misleading addiction claims

Thousands of lawsuits across the United States have accused a drug company owned by the billionaire Sackler family of using false claims to push highly addictive opioids on an unsuspecting nation, fueling the deadliest drug epidemic in U.S. history. 

Yet, even as its U.S. drugmaker collapses under the charges, another company owned by the family has used the same tactics to peddle its signature painkiller, OxyContin, in China, according to interviews with current and former employees and documents obtained by the Associated Press.

The documents and interviews indicate that representatives from the Sacklers' Chinese affiliate, Mundipharma, tell doctors that time-release painkillers like OxyContin are less addictive than other opioids—the same pitch that Purdue Pharma, the U.S. company owned by the family, admitted was false in court more than a decade ago. (medicalXpress, USA, 20.11.2019)

https://medicalxpress.com/news/2019-11-oxy-sales-china-driven-addiction.html

USA. Oklahoma Judge Shaves $107 Million Off Opioid Decision Against Johnson & Johnson

A global megacorporation best known for Band-Aids and baby powder is now on the hook for about $107 million less than originally anticipated over its role in Oklahoma's opioid crisis. (npr – National Public Radio, USA, 15.11.2019)

https://www.npr.org/2019/11/15/779439374/oklahoma-judge-shaves-107-million-off-opioid-decision-against-johnson-johnson

The Global Cannabis Report

The landscape of the global cannabis industry is shifting as quickly as the legislation that underpins it. The Prohibition Partners' The Global Cannabis Report, an industry first of its kind, analyses the key developments across the global cannabis sector and provides proprietary market forecasts across the continental markets: Africa, Asia, Europe, Latin America, North America and Oceania. The report predicts that the international cannabis market could be worth up to US$103.9 billion by 2024, and outlines key commercial opportunities for international operators and investors. (prohibitionpartners.com, 2019)

https://prohibitionpartners.com/reports/#the-global-cannabis-report

USA. Nicoteen Inc.: Juul disregarded early evidence it was hooking teens 

Juul executives knew young people were flocking to its breakthrough e-cigarette shortly after it went on sale in 2015, a former manager tells Reuters. Its nicotine blend was so potent, engineers devised a kill switch to limit the dosage – but the idea was shelved. (medscape.com, 07.11.2019)

https://www.medscape.com/viewarticle/920864

Schweiz. Schmerz, Sucht und Profit

Die Opioidkrise in den USA, das Pharmaimperium der Familie Sackler und deren Verbindungen in die Schweiz. Wie gefährlich ist das Schmerzmittel Oxycodon? (republik.ch, Schweiz, 30.10.2019)

https://www.republik.ch/2019/10/30/schmerz-sucht-und-profit

USA. Opioidkrise in den USA Das große Feilschen kommt erst noch 

Der Vergleich in Ohio ist nur der Auftakt: Amerikas Pharmaindustrie wird für ihre Mitverantwortung an der Opioidkrise Milliarden zahlen müssen. Doch Bundesstaaten und Gemeinden streiten schon jetzt um das Geld. (Spiegel online, 22.10.2019)

https://www.spiegel.de/wirtschaft/unternehmen/opioid-krise-in-den-usa-das-grosse-feilschen-kommt-erst-noch-a-1292657.html

USA. The Full Cost of the Opioid Crisis: $2.5 Trillion Over Four Years

October 26 marked National Prescription Drug Take Back Day, which provided Americans an opportunity to prevent drug misuse and theft by ridding their homes of potentially dangerous expired, unused, and unwanted prescription drugs. One of the most tangible examples of the dangers of misusing prescription drugs comes from the opioid crisis, which the Council of Economic Advisers (CEA) estimates cost $696 billion in 2018—or 3.4 percent of GDP—and more than $2.5 trillion for the four-year period from 2015 to 2018. These massive costs point to the nationwide economic destruction from America’s very human “crisis next door.” (The White House, 28.10.2019)

https://www.whitehouse.gov/articles/full-cost-opioid-crisis-2-5-trillion-four-years/

USA. Economic Impact of Non-Medical Opioid Use in the United States 

Annual Estimates and Projections for 2015 through 2019. (Society of Actuaries, USA, Oktober 2019)

https://www.soa.org/globalassets/assets/files/resources/research-report/2019/econ-impact-non-medical-opioid-use.pdf

USA. Nach Einstieg bei E-Zigarettenhersteller Juul: Marlboro-Konzern schreibt 4,5 Milliarden Dollar ab

Tabakkonzerne versprachen sich von der E-Zigarette Juul ein Milliardengeschäft. Für den Marlboro-Konzern Altria erwies sich das als extrem teurer Irrtum. (spiegel.de, 31.10.2019)

https://www.spiegel.de/wirtschaft/unternehmen/juul-e-zigarettenfirma-wird-fuer-marlboro-zum-milliardengrab-a-1294295.html

USA. Hospitals Take Shot at Opioid Makers Over Treating Uninsured for Addiction

While thousands of cities and counties have banded together to sue opioid makers and distributors in a federal court, another group of plaintiffs has started to sue on their own: hospitals.

Hundreds of hospitals have joined in a handful of lawsuits in state courts, seeing the state-based suits as their best hope for winning meaningful settlement money.

"The expense of treating overdose and opioid-addicted patients has skyrocketed, straining the resources of hospitals throughout our state," said Lee Bond, CEO of Singing River Health System in Mississippi in a statement. His hospital is part of a lawsuit in Mississippi. (medscape.com, 30.10.2019)

https://www.medscape.com/viewarticle/920597

USA. Opioidkrise: Pharmaunternehmen verhandeln in den USA über Strafzahlungen

New York – Kurz vor einem wichtigen US-Prozess um süchtig machende Schmerzmittel verhandeln drei Arzneimittelgroßhändler einem Zeitungsbericht nach mit Klägeranwälten über einen milliardenschweren Vergleich. (aerzteblatt.de, 16.10.2019)

https://www.aerzteblatt.de/nachrichten/106706/Opioidkrise-Pharmaunternehmen-verhandeln-in-den-USA-ueber-Strafzahlungen

USA. Vergleich in US-Rechtsstreit um Opioidkrise erzielt

Cleveland – Im bislang größten Rechtsstreit um die Opioidkrise in den USA haben die Kläger und mehrere Unternehmen heute eine gütliche Einigung erzielt. Dies teilte ein Richter in Cleveland im Bundesstaat Ohio mit. (aerzteblatt.de, 21.10.2019)

https://www.aerzteblatt.de/nachrichten/106841/Vergleich-in-US-Rechtsstreit-um-Opioidkrise-erzielt

USA. Opioidkrise in den USA: Reckitt Benckiser schließt Vergleich über 700 Millionen Dollar 

Die Pharmaindustrie soll die Opioidkrise in den USA mit mehr als 400.000 Toten ausgelöst haben. Im Streit über die Verantwortung hierfür hat mit Reckitt Benckiser nun ein weiteres Unternehmen einen Prozess abgewendet. (Spiegel online, 24.10.2019)

https://www.spiegel.de/wirtschaft/unternehmen/reckitt-benckiser-schliesst-in-us-opioidkrise-vergleich-ueber-700-millionen-dollar-a-1293055.html

USA. Pharma Sells States On ‘Netflix Model’ To Wipe Out Hep C. But At What Price?

When a long, black bus bearing the logo of drugmaker AbbVie rolls through Washington state next year, it will promote a new effort to eradicate hepatitis C infections.

The state is paying for the marketing campaign as part of a deal to give AbbVie the exclusive right to treat its citizens who have the potentially deadly liver disease. Armed with its medication, Mavyret, AbbVie beat out rivals Merck and Gilead Sciences in a blind bidding process.

It’s the second time this year that a state has struck a novel deal with a pharmaceutical company to obtain drugs that can cure hepatitis C ― with discounts from a price that came to market at $84,000 for a course of treatment.

The drugmakers are in a race to treat the 2.4 million people in the U.S, with the viral infection.  (KHN – Kaiser Health News, USA, 25.10.2019)

https://khn.org/news/pharma-sells-states-on-netflix-model-to-wipe-out-hep-c-but-at-what-price/